Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07115017 · ClinicalTrials.gov registry record

This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.

A clinical trial of Multiple Sclerosis, sponsored by Washington University School of Medicine.

Recruiting
Registry status
80
Enrollment target
1
Study location

NCT07115017 is a study of Multiple Sclerosis that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 80 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07115017, a study of Multiple Sclerosis, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

This study involves a Positron Emission Tomography (PET) scan using a new investigational radioactive tracer, \[18F\]-FZTA, to detect inflammation in the brain. The tracer will be tested in healthy younger adults and individuals with Multiple Sclerosis.

Conditions Studied

Interventions

  • DRUG [18F] FZTA

Study Locations (1)

Missouri

  • Washington University in St. Louis - St Louis

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-08-22
Est. Completion 2029-12

What the Registry Record Tells You About NCT07115017

The ClinicalTrials.gov registry entry for NCT07115017 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (86% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which [18F] FZTA is the first listed.

NCT07115017 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT07115017 about?

NCT07115017 is a clinical study titled "This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.". This study involves a Positron Emission Tomography (PET) scan using a new investigational radioactive tracer, \[18F\]-FZTA, to detect inflammation in the brain. The tracer will be tested in healthy younger adults and individuals with Multiple Sclerosis.

What is the current status of trial NCT07115017?

This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2025-08-22. Estimated completion is 2029-12.

What conditions does trial NCT07115017 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT07115017?

The interventions under investigation include: [18F] FZTA (DRUG).

Who is sponsoring clinical trial NCT07115017?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07115017 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.